#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Autologous haematopoietic stem cell transplant Congenital megacolon Cervix carcinoma Chondrosarcoma Cutaneous T-cell lymphoma recurrent Cold type haemolytic anaemia Acute promyelocytic leukaemia Mucous membrane pemphigoid Deafness bilateral Antiphospholipid syndrome Chronic lymphocytic leukaemia Renal disorder Pelizaeus-Merzbacher disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Cutaneous T-cell lymphoma stage II More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis I – Diagnostics Bronchopulmonary dysplasia – Treatment Retinoblastoma – Trials in Disease Chondrosarcoma metastatic – Treatment Hairy cell leukaemia – Diagnostics Progressive supranuclear palsy Pleural mesothelioma malignant – Diagnostics Hairy cell leukaemia Glomerulonephritis membranous – Treatment Rhabdomyosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    HYDROXYCHLOROQUINE Fluconazole Phenylbutyrate Povidone, Iodinated Alfacalcidol Mk-1088 Ademetionine Human Cancellous Bone ANXV Zelicapavir Dextran 70 Immunostimulants Zibotentan Ambroxol Hydrochloride Dinoprostone Prax-628 Riociguat Lasn01 LY3848575 Sapropterin Dihydrochloride More therapies…

    Learn about Your Condition

    Oxygen saturation Propionic acidaemia Malignant melanoma stage III Ovarian cancer metastatic Carotid artery stenosis Allergic respiratory disease Neuromuscular scoliosis Conjunctivitis Herpes simplex meningitis Type 2 diabetes mellitus Peripheral artery stenosis Coronary artery bypass Leiomyosarcoma metastatic Neuralgia Pemphigoid More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer stage IIIB

  • Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    Investigated Drugs:
    • Pemetrexed Disodium
    • Carboplatin
    • Cisplatin
    Austria Belgium Estonia France Ireland Italy +1

  • Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Interstitial lung disease
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Gemcitabine
    France

  • Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIA
    • Non-small cell lung cancer stage IIIB
    Investigated Drugs:
    • Pembrolizumab
    Italy

  • Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Zimberelimab
    Germany

  • Study on the Safety and Effectiveness of Azacitidine and Pembrolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer recurrent
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Azacitidine
    • Pembrolizumab
    Italy

  • Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    • Non-small cell lung cancer stage IIIB
    Investigated Drugs:
    • Durvalumab
    Germany
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!